TGNA:FRA
Transgene SA
€0,68
arrow_upward
+1,50%(+0,0100) 1 HR
12 Okt, 22.00.00 GMT+2 · EUR
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk TGNA...
Pembukaan
€0,68
Tinggi
€0,68
Rendah
€0,68
Kapitalisasi pasar
196,45 jt
Volume rata-rata
0,00
Volume
0,00
Harga tinggi dalam 52 minggu terakhir
€1,48
Harga rendah dalam 52 minggu terakhir
€0,60
EPS
-€0,17
Jumlah karyawan
152
Pembukaan
€0,68
Tinggi
€0,68
Rendah
€0,68
Kapitalisasi pasar
196,45 jt
Volume rata-rata
0,00
Volume
0,00
Harga tinggi dalam 52 minggu terakhir
€1,48
Harga rendah dalam 52 minggu terakhir
€0,60
EPS
-€0,17
Jumlah karyawan
152
Artikel berita
Dari sumber web dan partner berita
Kumparan.com
·
38 menit yang lalu
Wall Street Ditutup Bervariasi di Tengah Lonjakan Harga Minyak - kumparan.com
FXStreet
·
14 jam yang lalu
S&P 500: Kekuatan Pendapatan Mengimbangi Hambatan Imbal Hasil – HSBC
Investing.com Indonesia
·
6 jam yang lalu
Volume ETF S&P 500 Capai Titik Terendah dalam 22 Tahun
Profil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Tentang Transgene SA